. Author manuscript; available in PMC: 2021 May 10.

Published in final edited form as: J Am Coll Cardiol. 2020 Mar 16;75(14):1644–1656. doi: 10.1016/j.jacc.2020.02.009

TABLE 5.

Relationship between Change in Systolic Blood Pressure and Changes in Quality of Life and Biomarkers from Baseline to the 16 and 48-Week Visit.

	Total N	Change in Parameter per 10 mmHg Reduction in Systolic Blood Pressure from Baseline to the 16-Week Visit Fully-adjusted Model Beta-coefficient (95% CI)^*^{^}	P for treatment interaction	Change in Parameter per 10 mmHg Reduction in Systolic Blood Pressure from Baseline to the 48-Week Visit Fully-adjusted Model Beta-coefficient (95% CI)^*^{^}	P for treatment interaction
Quality of Life
• KCCQ-OSS (change in score)	4507	+0.1 (−0.2, +0.4), p=0.40	0.10	+0.1 (−0.3, +0.3), p=0.92	0.30
Biomarkers
• NT-proBNP (% change)	3222	−3.8% (−5.4%, −2.2%), p<0.001	0.75	−2.1% (−3.8%, −0.2%), p=0.027	0.72
• High-sensitivity troponin T (% change)	1205	+0.9% (−0.3%, +2.0%), p=0.13	0.98	+1.0% (−0.4%, +2.4%), p=0.16	0.98

CI, confidence interval; KCCQ-OSS, Kansas City Cardiomyopathy Questionnaire Overall Summary Score.

Expressed as change in the parameter (KCCQ-OSS, NT-proBNP, or high-sensitivity troponin T) per 10 mmHg decrease in systolic blood pressure from baseline to the specified visit (16 or 48 week visit). All analyses controlled for and baseline blood pressure.

^{^}

Additionally adjusted for baseline covariates including region, atrial fibrillation, creatinine, diabetes mellitus, New York Heart Association class, heart rate, sex, age, race, current smoking, number of anti-hypertensive medications, and treatment group.